Stereotaxis, Inc. (STXS) — SEC Filings
Stereotaxis, Inc. (STXS) — 27 SEC filings. Latest: 8-K (Apr 15, 2026). Includes 14 8-K, 6 10-Q, 2 DEFA14A.
View Stereotaxis, Inc. on SEC EDGAR
Overview
Stereotaxis, Inc. (STXS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 12, 2025: Stereotaxis, Inc. reported a net loss of $6.463 million for the three months ended September 30, 2025, a slight increase from the $6.190 million net loss in the same period of 2024. Total revenue decreased to $7.464 million in Q3 2025 from $9.196 million in Q3 2024, primarily due to a significant dr
Sentiment Summary
Across 27 filings, the sentiment breakdown is: 25 neutral, 2 mixed. The dominant filing sentiment for Stereotaxis, Inc. is neutral.
Filing Type Overview
Stereotaxis, Inc. (STXS) has filed 14 8-K, 2 DEFA14A, 6 10-Q, 2 DEF 14A, 2 10-K, 1 SC 13G/A with the SEC between Feb 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (27)
Risk Profile
Risk Assessment: Of STXS's 24 recent filings, 0 were flagged as high-risk, 12 as medium-risk, and 12 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $7.464M |
| Net Income | -$6.463M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $10.506M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Industry Context
Stereotaxis operates in the highly competitive medical device market, specifically focusing on robotic navigation for minimally invasive procedures. The industry is characterized by rapid technological advancements, stringent regulatory hurdles, and a need for significant capital investment. Key trends include the expansion of robotic surgery into new clinical areas like cardiology and neurology, and the increasing demand for integrated solutions combining hardware, software, and disposables.
Top Tags
8-k (4) · sec-filing (4) · 10-Q (4) · financial-reporting (4) · Medical Devices (3) · financial-condition (3) · financials (3) · medical-devices (3) · Stereotaxis (3) · Electrophysiology (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $6.463M | Increased from $6.190M in Q3 2024 |
| Total Revenue (Q3 2025) | $7.464M | Decreased from $9.196M in Q3 2024 |
| Systems Revenue (Q3 2025) | $1.861M | Significant drop from $4.391M in Q3 2024 |
| Disposables, Service & Accessories Revenue (Q3 2025) | $5.603M | Increased from $4.805M in Q3 2024 |
| Total Revenue (YTD Sep 2025) | $23.735M | Increased from $20.578M in YTD Sep 2024 |
| Disposables, Service & Accessories Revenue (YTD Sep 2025) | $16.872M | Increased from $13.335M in YTD Sep 2024 |
| Cash and Cash Equivalents (Sep 30, 2025) | $10.506M | Decreased from $12.217M at Dec 31, 2024 |
| Net Cash Used in Operating Activities (YTD Sep 2025) | $9.716M | Slightly improved from $9.763M in YTD Sep 2024 |
| Accumulated Deficit (Sep 30, 2025) | $577.837M | Increased from $561.725M at Dec 31, 2024 |
| Outstanding Shares (Oct 31, 2025) | 93,324,763 | Increased from 85,326,557 shares at Dec 31, 2024 |
| Total Revenue (Q2 2025) | $8.798M | Increased 95.4% from $4.502M in Q2 2024 |
| Systems Revenue (Q2 2025) | $3.038M | Increased from $0.240M in Q2 2024, indicating strong system adoption |
| Disposables, Service & Accessories Revenue (Q2 2025) | $5.760M | Increased from $4.262M in Q2 2024, showing growth in recurring revenue |
| Net Loss (Q2 2025) | $(3.826M) | Improved from $(5.833M) in Q2 2024 |
| Total Revenue (Six Months Ended June 30, 2025) | $16.270M | Increased from $11.382M in the prior year period |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Stereotaxis, Inc. (STXS)?
Stereotaxis, Inc. has 27 recent SEC filings from Feb 2024 to Apr 2026, including 14 8-K, 6 10-Q, 2 DEFA14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of STXS filings?
Across 27 filings, the sentiment breakdown is: 25 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Stereotaxis, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Stereotaxis, Inc. (STXS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Stereotaxis, Inc.?
Key financial highlights from Stereotaxis, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for STXS?
The investment thesis for STXS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Stereotaxis, Inc.?
Executive information for Stereotaxis, Inc. is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Stereotaxis, Inc. stock?
Of STXS's 24 assessed filings, 0 were flagged high-risk, 12 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Stereotaxis, Inc.?
Forward guidance and predictions for Stereotaxis, Inc. are extracted from SEC filings as they are enriched.